Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare momentum candidate with shareholder support: stock rose about 23% over 21 trading days and is near recent highs. Q1 2026 revenue was $328.5M with improved margins and solid cash flow, while management authorized a new $200M repurchase program.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Cash Flow ⢠Dilution Risk PGNY shows improving margins, strong cash flow and low debt, but elevated valuation, weakening liquidity/equity, and heavy stock-based compensation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Resistance test ⢠Support rebound Support Level: $25.40â$25.70 Resistance Level: $27.80â$28.10 PGNY gained 4.5% over the last month and remains constructive above $26.53, with a break above $28.10 bullish and a drop below $25.40 bearish.
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠Analyst Upside ⢠Margin Expansion Progyny attracted new institutional investors and favorable analyst support, reinforcing a positive outlook driven by fertility-benefits leadership, growth, and margin expansion.
AI Summary
PGNY is a cash-generative, margin-expanding fertility-benefits platformânot simply a growth storyâbut its premium valuation hinges on a prompt recovery in treatment utilization; investors should await confirmation of September demand normalization and buybacks that offset heavy stock-based compensation before underwriting a rerating.
Description
Progyny is a U.S. benefits management company that provides employer-sponsored fertility and family-building programs through tailored plan design, concierge-style member support, and a curated network of reproductive specialists. The company also offers an integrated pharmacy service for treatment medications and administers employer-funded surrogacy and adoption reimbursement programs. Incorporated in 2008 as Auxogyn and renamed Progyny in 2015, it is headquartered in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 20 | Jul 27 | PGNY | Progyny, Inc. | Healthcare momentum candidate with shareholder support: stock rose about 23% over 21 trading days and is near recent highs. Q1 2026 revenue was $328.5M with improved margins and solid cash flow, while management authorized a new $200M repurchase program. | Closed | -0.6% |
| Jul 13 | Jul 20 | PGNY | Progyny, Inc. | Healthcare services momentum candidate: stock gained about 23.7% over 21 trading days and closed at a short-term high, supported by record Q1 2026 revenue of $328.5M, a new $200M buyback, healthy free cash flow, and favorable estimate-revision headlines on 2026-07-09. | Closed | -0.7% |
| Jul 2 | Jul 9 | PGNY | Progyny, Inc. | Favorable momentum plus capital return: stock is up about 19% over 21 trading days at a fresh short-term high, Q1 revenue reached a record $328.5M, free cash flow was $39.6M, leverage is low, and the board approved a new $200M buyback. | Closed | +2.8% |
| May 11 | May 18 | PGNY | Progyny, Inc. | Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through. | Closed | +6.7% |